Table 5.
Baseline predictors factors of SPARCC spine score and SPARCC SSJ score at T24.
| SPARCC spine score | ||||
|---|---|---|---|---|
| Independent variables | Univariable analysis | Multivariable analysis | ||
| coeff (IC) | p | coeff (IC) | p | |
| Female sex | −0.14 (−0.56, 0.28) | 0.511 | – | – |
| LBP onset age | −0.01 (−0.04, 0.00) | 0.152 | −0.02 (−0.05, 0.00) | 0.124 |
| Duration of LBP | 0.02 (−0.01, 0.05) | 0.154 | 0.02 (−0.01, 0.05) | 0.192 |
| HLA-B27+ | 0.35 (−0.06, 0.78) | 0.099 | 0.12 (−0.33, 0.58) | 0.582 |
| Increased ESR/CRP | 0.11 (−0.31, 0.54) | 0.583 | – | – |
| BASDAI>=4 | –0.39(−0.81, 0.01) | 0.058 | –0.33 (–.73, 0.07) | 0.104 |
| Use of NSAIDs | 0.60 (–0.26, 1.48) | 0.168 | 0.88 (0.01, 1.75) | 0.046 |
| SPARCC SIJ>2 | 0.44 (−0.42, 0.65) | 0.311 | – | – |
| SPARCC SSJ score | ||||
| Independent variables | Univariable analysis | Multivariable analysis | ||
| coeff (IC) | p | coeff (IC) | p | |
| Female sex | −3.59 (−9.54, 2.36) | 0.233 | – | – |
| LBP onset age | −0.36 (−0.72, –0.004) | 0.047 | −0.25 (−0.60, 0.08) | 0.140 |
| Duration of LBP | 0.00 (−0.48, 0.49) | 0.980 | – | – |
| HLA-B27+ | 9.41 (3.64, 15.18) | 0.002 | 8.87 (3.08, 14.65) | 0.003 |
| Increased ESR/CRP | 4.46 (–1.59, 10.51) | 0.146 | 5.74 (0.15, 11.34) | 0.044 |
| BASDAI > = 4 | −3.94 (−9.85, 1.96) | 0.187 | −3.14 (−8.55, 2.26) | 0.250 |
| Use of NSAIDs | 3.87 (−6.09, 13.84) | 0.441 | – | – |
LBP, low back pain; HLA-B27, human leukocyte antigen B27; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BASDAI, bath ankylosing spondylitis disease activity index; NSAIDs, non-steroidal antiinflammatory drugs; SPARCC, spondyloarthritis research consortium of Canada; SIJ, sacroiliac joints; T24, 24 months.